Literature DB >> 12438585

Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

Carole Balmelli1, Stéphane Demotz, Hans Acha-Orbea, Pierre De Grandi, Denise Nardelli-Haefliger.   

Abstract

Vaccination by the nasal route has been successfully used for the induction of immune responses. Either the nasal-associated lymphoid tissue (NALT), the bronchus-associated lymphoid tissue, or lung dendritic cells have been mainly involved. Following nasal vaccination of mice with human papillomavirus type 16 (HPV16) virus-like-particles (VLPs), we have previously shown that interaction of the antigen with the lower respiratory tract was necessary to induce high titers of neutralizing antibodies in genital secretions. However, following a parenteral priming, nasal vaccination with HPV16 VLPs did not require interaction with the lung to induce a mucosal immune response. To evaluate the contribution of the upper and lower respiratory tissues and associated lymph nodes (LN) in the induction of humoral responses against HPV16 VLPs after nasal vaccination, we localized the immune inductive sites and identified the antigen-presenting cells involved using a specific CD4(+) T-cell hybridoma. Our results show that the trachea, the lung, and the tracheobronchial LN were the major sites responsible for the induction of the immune response against HPV16 VLP, while the NALT only played a minor role. Altogether, our data suggest that vaccination strategies aiming to induce efficient immune responses against HPV16 VLP in the female genital tract should target the lower respiratory tract.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438585      PMCID: PMC136716          DOI: 10.1128/jvi.76.24.12596-12602.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Uptake of small resin particles (1-5 microns diameter) by the alimentary canal of the calf.

Authors:  J M PAYNE; B F SANSOM; R J GARNER; A R THOMSON; B J MILES
Journal:  Nature       Date:  1960-11-12       Impact factor: 49.962

2.  Bronchial lymphoid tissue. I. Morphologic characteristics.

Authors:  J Bienenstock; N Johnston; D Y Perey
Journal:  Lab Invest       Date:  1973-06       Impact factor: 5.662

3.  Papillomavirus-like particles induce acute activation of dendritic cells.

Authors:  P Lenz; P M Day; Y Y Pang; S A Frye; P N Jensen; D R Lowy; J T Schiller
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

4.  Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison.

Authors:  R W Chesnut; S M Colon; H M Grey
Journal:  J Immunol       Date:  1982-04       Impact factor: 5.422

5.  Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin).

Authors:  K Matsuo; T Yoshikawa; H Asanuma; T Iwasaki; Y Hagiwara; Z Chen; S E Kadowaki; H Tsujimoto; T Kurata; S I Tamura
Journal:  Vaccine       Date:  2000-06-01       Impact factor: 3.641

6.  Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.

Authors:  V Revaz; J Benyacoub; W M Kast; J T Schiller; P De Grandi ; D Nardelli-Haefliger
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

7.  Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli.

Authors:  D M Shaw; B Gaerthé; R J Leer; J G Van Der Stap; C Smittenaar; M Heijne Den Bak-Glashouwer; J E Thole; F J Tielen; P H Pouwels; C E Havenith
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

8.  Structural differences in cell surface T25 polypeptides from thymocytes and cloned T cells.

Authors:  M Sarmiento; M R Loken; F W Fitch
Journal:  Hybridoma       Date:  1981

9.  Expression of interleukin-2 receptors as a differentiation marker on intrathymic stem cells.

Authors:  R Ceredig; J W Lowenthal; M Nabholz; H R MacDonald
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

10.  Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition.

Authors:  J W Kappler; B Skidmore; J White; P Marrack
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  12 in total

1.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

2.  Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge.

Authors:  D L Bolton; K Song; R L Wilson; P A Kozlowski; G D Tomaras; B F Keele; R V Lovingood; S Rao; M Roederer
Journal:  Mucosal Immunol       Date:  2011-10-26       Impact factor: 7.313

3.  Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.

Authors:  Dirk Kuck; Tobias Lau; Barbara Leuchs; Andrea Kern; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

4.  Parenteral is more efficient than mucosal immunization to induce regression of human papillomavirus-associated genital tumors.

Authors:  Loane Decrausaz; Sonia Domingos-Pereira; Mélanie Duc; Martine Bobst; Pedro Romero; John T Schiller; Patrice Jichlinski; Denise Nardelli-Haefliger
Journal:  Int J Cancer       Date:  2011-08-01       Impact factor: 7.396

5.  Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.

Authors:  Stefan Fernandez; Emily D Cisney; Shannan I Hall; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

6.  Airways infection with virulent Mycobacterium tuberculosis delays the influx of dendritic cells and the expression of costimulatory molecules in mediastinal lymph nodes.

Authors:  Gina S García-Romo; Alexander Pedroza-González; Diana Aguilar-León; Hector Orozco-Estevez; Bart N Lambrecht; Iris Estrada-Garcia; Leopoldo Flores-Romo; Rogelio Hernández-Pando
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

7.  Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.

Authors:  Hakim Echchannaoui; Matteo Bianchi; David Baud; Martine Bobst; Jean-Christophe Stehle; Denise Nardelli-Haefliger
Journal:  Infect Immun       Date:  2008-03-10       Impact factor: 3.441

8.  CC chemokine receptor 7 expression by effector/memory CD4+ T cells depends on antigen specificity and tissue localization during influenza A virus infection.

Authors:  Gudrun F Debes; Kerstin Bonhagen; Thorsten Wolff; Ute Kretschmer; Stefan Krautwald; Thomas Kamradt; Alf Hamann
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoPc phenotype in Salmonella enterica serovar Typhimurium.

Authors:  David Baud; Jalil Benyacoub; Véronique Revaz; Menno Kok; Françoise Ponci; Martine Bobst; Roy Curtiss; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

10.  Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.

Authors:  Dominique Fraillery; David Baud; Susana Yuk-Ying Pang; John Schiller; Martine Bobst; Nathalie Zosso; Françoise Ponci; Denise Nardelli-Haefliger
Journal:  Clin Vaccine Immunol       Date:  2007-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.